Claims
- 1. A compound of formula I ##STR3## wherein R.sub.1 is C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkoxy, triflate, pyridyl or phenyl where the phenyl moiety is optionally substituted by one or more substituents selected from cyano, halogen and C.sub.1-4 alkyl;
- R.sub.2 is hydrogen, C.sub.1-6 alkyl, 1-oxo-C.sub.1-6 alkyl or carboxy-1-oxo-C.sub.1-6 alkyl;
- R.sub.3 is hydrogen, halogen or C.sub.1-6 alkyl optionally substituted by one or more substituents selected form C.sub.1-6 alkoxy and halogen;
- R.sub.4 is hydrogen, C.sub.1-6 alkyl, 1-oxo-C.sub.1-6 alkyl or carboxy-1-oxo-C.sub.1-6 alkyl; and
- X is (H,OH), O or NOH;
- or a pharmaceutically acceptable salt or solvate thereof.
- 2. A compound according to claim 1, wherein R.sub.1 is phenyl, triflate or C.sub.1-6 alkyl; R.sub.2 is hydrogen; R.sub.3 is hydrogen, halogen, C.sub.1-6 alkyl optionally substituted by C.sub.1-6 alkoxy; R.sub.4 is hydrogen or methyl; X is O; or a pharmaceutically acceptable salt or solvate thereof.
- 3. A compound according to claim 1, wherein R.sub.1 is phenyl or C.sub.1-6 alkyl; R.sub.2 is hydrogen; R.sub.3 is C.sub.1-6 alkyl; R.sub.4 is hydrogen or C.sub.1-6 alkyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.
- 4. A compound according to claim 1 wherein R.sub.1 is phenyl, t-butyl, isopropyl or methyl; R.sub.2 is hydrogen; R.sub.3 is methyl; R.sub.4 is hydrogen or methyl; and X is O; or a pharmaceutically acceptable salt or solvate thereof.
- 5. A compound according to claim 1, which is selected from:
- (11.beta.,16.alpha.,17.beta.)-11-(4-t-butylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;
- (11.beta.,16.alpha.,17.beta.)-11-(4-isopropylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;
- (11.beta.,16.alpha.,17.beta.)-11-(4-methylphenyl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;
- (11.beta.,16.alpha.,17.beta.)-11-(1,1'-biphenyl-4-yl)-16,17-dihydroxy-17-(1-propynyl)estra-4,9-dien-3-one;
- (11.beta.,16.alpha.,17.beta.)-16,17-dihydroxy-11-[4-(trifluoromethylsulfonyl)oxy]phenyl]-17-(1-propynyl)estra-4,9-dien-3-one;
- or a pharmaceutically acceptable salt or solvate thereof.
- 6. A pharmaceutical formulation comprising a compound according to any of claims 1 to 5, together with a pharmaceutically acceptable carrier.
- 7. A process for the preparation of a compound of formula I as defined in any of claims 1 to 5, comprising dehydration and deprotection of a compound of formula II ##STR4## wherein P is a protected keto group and R.sub.5 is a group R.sub.4 as defined in claim 1 or a suitably protected R.sub.4 group;
- optionally followed by treatment with a suitable reducing agent or with a suitable oximating agent; and optional conversion into a pharmaceutically acceptable salt or solvate.
- 8. A compound of formula II ##STR5## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined in claim 1, R.sub.5 is a group R.sub.4 as defined in claim 1 or a suitably protected R.sub.4 group and P is a protected keto group.
- 9. A method fox treating glucocorticoid-dependent diseases or symptoms, comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1-5.
- 10. A process for preparing a pharmaceutical formulation, comprising admixing a (compound according to any one of claims 1-5 with a pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
97200098 |
Jan 1997 |
EPX |
|
Parent Case Info
This application is a 371 of PCT/EP98/00377 filed Jan. 3, 1998.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP98/00377 |
1/13/1998 |
|
|
7/14/1999 |
7/14/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/31702 |
7/23/1998 |
|
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 190 759 |
Aug 1986 |
EPX |
33 07 143 |
Sep 1983 |
DEX |